17 completed, 16 recruiting, 9 terminated, 7 active not recruiting. 37 Phase 2, 26 Phase 1, 5 Phase 3, 1 Early Phase 1.
Follow Retifanlimab: new trials by email Literature Review of Retifanlimab trials Research Report on Retifanlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-01 | 2026-08-14 |
| Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer | Phase 2 | Not yet recruiting | Polly A. Niravath, MD | 30 | 2026-12-31 | 2026-08-19 |
| NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer Retifanlimab, Zanzalintinib - Colon Cancer Metastatic | Phase 2 | Not yet recruiting | Northwell Health | 26 | 2026-08-30 | 2026-07-01 |
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 33 | 2026-06-23 | 2026-06-24 |
| ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab - Anal Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Jennifer Dorth | 33 | 2026-06-19 | 2026-08-14 |
| Retifanlimab and Ruxolitinib In Solid Malignancies Ruxolitinib, Retifanlimab - Non Small Cell Lung Carcinoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 40 | 2026-01-08 | 2026-01-13 |
| 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Retifanlimab, Chemotherapy, 9-ING-41 - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Anwaar Saeed | 12 | 2025-09-22 | 2026-09-24 |
| A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab - Breast Cancer | Phase 1 | Suspended | M.D. Anderson Cancer Center | 24 | 2025-08-13 | 2026-10-05 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors INCB177054, Retifanlimab - Solid Tumors, Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 9 | 2025-06-30 | 2026-09-02 |
| A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma Plixorafenib, Retifanlimab - BRAF V600E Mutation | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2025-04-07 | 2026-09-22 |
| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Bevacizumab, Biospecimen Collection, Computed Tomography - Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 134 | 2024-10-02 | 2024-11-19 |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma | Phase 2 | Recruiting | Lund University Hospital | 33 | 2024-06-20 | 2026-08-27 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Axatilimab, Biopsy, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 38 | 2024-05-21 | 2026-07-08 |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-03-26 | 2026-10-16 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734, Cetuximab, Retifanlimab - Solid Tumors | Phase 1 | Recruiting | Incyte Corporation | 710 | 2024-01-04 | 2026-07-22 |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site - Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | BriaCell Therapeutics Corporation | 404 | 2023-12-05 | 2026-09-02 |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Biopsy, Biospecimen Collection, Computed Tomography - Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | University of Washington | 12 | 2023-11-08 | 2026-08-06 |
| Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation device - Unmethylated Glioblastoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 27 | 2023-10-27 | 2026-05-04 |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab - Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2023-05-03 | 2023-05-09 |
Showing 20 of 59. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Glioblastoma (5) · Neoplasm Metastasis (5) · Breast Neoplasms (4) · Carcinoma, Merkel Cell (4) · Squamous Cell Carcinoma of Head and Neck (4) · Anus Neoplasms (3) · Carcinoma, Squamous Cell (3) · Colorectal Neoplasms (3) · Glioma (3) · Head and Neck Neoplasms (3) · Pancreatic Neoplasms (3) · Astrocytoma (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2)
Incyte Corporation (18) · MacroGenics (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Anwaar Saeed (2) · BriaCell Therapeutics Corporation (2) · Incyte Biosciences International Sà rl (2) · M.D. Anderson Cancer Center (2) · University of Washington (2) · Washington University School of Medicine (2) · Academic and Community Cancer Research United (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Ariceum Therapeutics GmbH (1) · Gruppo Oncologico del Nord-Ovest (1) · Incyte Biosciences Japan GK (1) · Institut Bergonié (1)
United States (46) · Italy (13) · France (10) · Spain (10) · Belgium (7) · Germany (7) · Poland (7) · Australia (6) · United Kingdom (6) · Denmark (5) · Hungary (4) · Japan (4) · Netherlands (4) · Norway (4) · Bulgaria (3)
Anwaar Saeed, MD (2) · Diane Hershock, MD (2) · Ashley L. Ward, MD (1) · Ashley Ward, MD (1) · Bora Lim, MD (1) · Daniel M Halperin, MD (1) · Eiji Ueda, MD, PhD, MBA (1) · Federica Morano, MD (1) · George E Peoples, MD, FACS (1) · Gino K In, MD (1) · Giuseppe Del Priore, MD MPH (1) · Hanneke WM van Laarhoven, MD, PhD (1) · Harshabad Singh, MBBS MD (1) · Ilona Rybicka, MD (1)
PMID 33263418, PMID 34951522, PMID 35176457, PMID 35414591, PMID 35816951, PMID 36091159, PMID 36104795, PMID 38904277, PMID 40517007, PMID 40796223, PMID 40983066, PMID 41811823, PMID 42201333
2023 (4), 2018 (2), 2019 (2), 2017 (1), P30CA014089 (1), P30CA015083 (1), P30CA072720 (1), P50CA062924 (1)